A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Trial details
- Registry ID
- NCT04126473
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleNCT04126473 | ELOX | Phase 2 | Completed | 2022-04-06Actual |
| A Study of ELX-02 in Patients With Alport SyndromeNCT05448755 | ELOX | Phase 2 | Completed | 2023-09-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |